STOCK TITAN

Sohm Inc - SHMN STOCK NEWS

Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.

SOHM Inc (SHMN) delivers innovative solutions at the intersection of generic pharmaceuticals and advanced gene editing. This news hub provides investors and industry observers with timely updates on the company’s financial developments, research milestones, and strategic initiatives.

Access authoritative reports on earnings announcements, regulatory filings, and technology advancements like the ABBIE genome editing system. Stay informed about partnerships with leading institutions and progress in CAR-T cell therapy applications.

Our curated collection features press releases detailing manufacturing expansions, cosmeceutical product launches, and biotech collaborations. Discover updates on patent approvals, clinical trial developments, and market expansion strategies.

Bookmark this page for streamlined access to verified information about SHMN’s dual focus areas. Check regularly for new insights into how SOHM Inc navigates the evolving biopharmaceutical landscape through its integrated business model.

Rhea-AI Summary

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has signed a manufacturing and supply agreement for skincare topical products with new export customers. The company has dispatched its first initial purchase order of 7,500 units to a new Far East customer, which is expected to generate over a quarter million in revenue during 2024. SOHM's Carlsbad facility will handle production for ongoing regular orders.

The agreement covers human prescription topical treatments for skin care, acne, exfoliation, and anti-aging. SOHM plans to expand its business through private label agreements and CDMO activities with other domestic and export customers. The company aims to capture a substantial market share in 2024, building on its success with other product lines, including the recently introduced ABBIE kits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced a new collaboration with Stanford University. This partnership aims to advance cell engineering and gene editing through SOHM's ABBIE Technology. The collaboration will involve joint research projects, knowledge-sharing initiatives, and technology development programs.

Dr. David Aguilar, COO of SOHM, expressed excitement about the partnership, stating that it will amplify their impact and foster innovation. Specific projects and initiatives under this collaboration are expected to be unveiled in the coming months. This strategic alliance combines SOHM's innovative prowess with Stanford's expertise to tackle challenges in gene editing development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary

SOHM has announced promising preliminary data from their ABBIE genome editing technology, showcasing successful engineering of a CAR-T cell from a healthy donor that killed lung cancer cells in experimental models. This breakthrough, presented at the 2024 AACR conference, highlights ABBIE's novel approach, utilizing mRNA or purified protein delivery instead of traditional virus-based systems. This could offer a more efficient and less toxic method for developing cancer immunotherapies. The market for such therapies is projected to grow significantly, with CAR T-cell therapy costs ranging from $373,000 to $475,000 per patient.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
Rhea-AI Summary

SOHM targets the release of its revolutionary ABBIE genome editing kits by Q3 2024. ABBIE, a retroviral integrase with a linked dCas9 DNA binding domain, promises precise and targeted integration of donor DNA into cell genomes. This breakthrough technology could significantly advance genetic engineering, offering new treatment possibilities for genetic diseases and novel therapies. The company expects high demand and significant revenue from the first generation of ABBIE kits, projecting thousands of units sold and millions in revenue. Additional related products are also under development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (SHMN) collaborates with Coastar Therapeutics to advance genome editing technology using innovative drug delivery systems. The partnership aims to enhance gene editing efficiency and safety through the integration of Coastar's red blood cell membrane derived carriers with SOHM's ABBIE genome editing technology, offering new possibilities for gene therapy and precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces filing of provisional patent application for ABBIE 'Smart Gene-Editing' platform. The gene-editing market was valued at $5.3 billion in 2023 and is expected to grow to $10.8 billion by 2028. The company aims to resolve off-target gene-editing limitations with ABBIE, utilizing the latest enzymes, guide RNAs, and graphene-based nanomaterials. ABBIE's technology aims to improve precision, reduce immune response, and extend applications beyond human health, revolutionizing genome editing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
none
News
Rhea-AI Summary
SOHM, Inc. (SHMN) announced its business outlook for 2024, detailing market backgrounds, business strategies, and revenue expectations for its OTC Self-care, Branded Generics, CDMO Services, and Biotech Gene-Editing Kit business units.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (SHMN) announces the opening of a new CDMO GMP manufacturing facility in Carlsbad, California, to meet the growing demand for its pharmaceutical, nutraceutical, and cosmeceutical products. The facility will have an initial daily capacity of 500 gallons and aims to complete the engineering batches produced in the San Diego facility by Q1 2024. The company's strategic plan to enhance production capacity and efficiency aligns with the expanding bio and pharma CDMO market, which is expected to grow to $309 billion by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces the launch of 13 new SOHM Nutrients’ Brand Chewables, targeting the global vitamin gummies market. The global vitamins market, valued at $6.84 billion in 2022, is expected to reach $18.76 billion by 2031, with a CAGR of 12.06% between 2023-2031. The new chewables offer bone health, skin health, immune boost, mineral replenishment, and sleep aid, featuring convenience, taste, and sought-after ingredients. They will be available for retail and bulk purchases through Amazon.com and the company’s Direct-to-Consumers Website at competitive prices. Dr. David Aguilar, COO of SOHM, anticipates a significant impact on sales, with plans to announce additional OTC Self-care products launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
Rhea-AI Summary
SOHM, Inc. announces collaboration with University of Arizona Center for Innovation to develop ABBIE gene-editing kit technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
Sohm Inc

OTC:SHMN

SHMN Rankings

SHMN Stock Data

1.34M
1.58B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Corona